Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences.

BACKGROUND Ductal carcinoma in situ (DCIS) recurs in the same breast following breast-conserving surgery in 5%-25% of patients, with the rate influenced by the presence or absence of involved surgical margins, tumor size and nuclear grade, and whether or not radiation therapy was performed. A recurrent lesion arising soon after excision of an initial DCIS may reflect residual disease, whereas in situ tumors arising after longer periods are sometimes considered to be second independent events. The purpose of this study was to determine the clonal relationship between initial DCIS lesions and their recurrences. METHODS Comparative genomic hybridization (CGH) was used to compare chromosomal alterations in 18 initial DCIS lesions (presenting in the absence of invasive disease) and in their subsequent ipsilateral DCIS recurrences (detected from 16 months to 9.3 years later). RESULTS Of the 18 tumor pairs, 17 showed a high concordance in their chromosomal alterations (median = 81%; range = 65%-100%), while one case showed no agreement between the paired samples (having two and 20 alterations, respectively). Morphologic characterization of the DCIS pairs showed clear similarities. The mean number of CGH changes was greater in the recurrent tumors than in the initial lesions (10.7 versus 8.8; P =.019). The most common changes in both the initial and the recurrent in situ lesions were gains involving chromosome 17q and losses involving chromosomes 8p and 17p. The degree of concordance was independent of the time interval before recurrence and of the presence of positive surgical margins. CONCLUSIONS In this study, DCIS recurrences were clonally related to their primary lesions in most cases. This finding is consistent with treatment paradigms requiring wide surgical margins and/or postoperative radiation therapy.

[1]  D Sudar,et al.  Comparative Genomic Hybridization , 1995, Current protocols in human genetics.

[2]  Ash A. Alizadeh,et al.  Genome-wide analysis of DNA copy-number changes using cDNA microarrays , 1999, Nature Genetics.

[3]  S. Martino,et al.  The influence of margin width on local control of ductal carcinoma in situ of the breast. , 1999, The New England journal of medicine.

[4]  Geoff Delaney M.B.B.S.,et al.  Predictors of local recurrence after treatment of ductal carcinoma in situ - A meta-analysis , 1999 .

[5]  J. Manola,et al.  Predictors of local recurrence following excision alone for ductal carcinoma in situ , 1999, Cancer.

[6]  J. Boyages,et al.  Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. , 1999, Cancer.

[7]  R E Hermann,et al.  Predicting the likelihood of residual disease in women treated for ductal carcinoma in situ. , 1999, Journal of the American College of Surgeons.

[8]  E. Gabrielson,et al.  Comparison of loss heterozygosity in primary and recurrent ductal carcinoma in situ of the breast. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[9]  P. Carroll,et al.  Genetic alterations in primary bladder cancers and their metastases. , 1998, Cancer research.

[10]  J. Stanford,et al.  Risk of recurrence after ductal carcinoma in situ of the breast. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[11]  P. O’Connell,et al.  Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. , 1998, Journal of the National Cancer Institute.

[12]  J. Varley,et al.  Loss of heterozygosity at chromosome 9p in ductal carcinoma in situ and invasive carcinoma of the breast. , 1998, British Journal of Cancer.

[13]  R. Sutherland,et al.  Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  N. Bundred,et al.  The importance of complete excision in the prevention of local recurrence of ductal carcinoma in situ. , 1998, British Journal of Cancer.

[15]  B. Fowble The Results of Conservative Surgery and Radiation for Mammographically Detected Ductal Carcinoma In Situ , 1997 .

[16]  F. Waldman,et al.  Chromosomal alterations in ulcerative colitis-related neoplastic progression. , 1997, Gastroenterology.

[17]  Takafumi Nishizaki,et al.  Genetic alterations in primary breast cancers and their metastases: Direct comparison using modified comparative genomic hybridization , 1997, Genes, chromosomes & cancer.

[18]  O. Kallioniemi,et al.  Genetic changes in intraductal breast cancer detected by comparative genomic hybridization. , 1997, The American journal of pathology.

[19]  J. Varley,et al.  Comparative genomic hybridisation of ductal carcinoma in situ of the breast: identification of regions of DNA amplification and deletion in common with invasive breast carcinoma , 1997, Oncogene.

[20]  E A Sickles,et al.  Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. , 1997, Journal of the National Cancer Institute.

[21]  A. Patchefsky,et al.  Results of conservative surgery and radiation for mammographically detected ductal carcinoma in situ (DCIS). , 1997, International journal of radiation oncology, biology, physics.

[22]  E. Gabrielson,et al.  Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast. , 1996, Cancer research.

[23]  E Gabrielson,et al.  Genetic divergence in the clonal evolution of breast cancer. , 1996, Cancer research.

[24]  K. Kerlikowske,et al.  Incidence of and treatment for ductal carcinoma in situ of the breast. , 1996, JAMA.

[25]  R. Brown,et al.  Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis. , 1995, Journal of the National Cancer Institute.

[26]  N. Phillips,et al.  Allelic loss and the progression of breast cancer. , 1995, Cancer research.

[27]  S. Hilsenbeck,et al.  Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. , 1995, The American journal of pathology.

[28]  A. Sahin,et al.  Comparative allelotype of in situ and invasive human breast cancer: high frequency of microsatellite instability in lobular breast carcinomas. , 1995, Cancer research.

[29]  M. Silverstein,et al.  Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. , 1995, European journal of cancer.

[30]  N. Phillips,et al.  Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. , 1995, Cancer research.

[31]  J. Warneke,et al.  Influence of local treatment on the recurrence rate of ductal carcinoma in situ. , 1995, Journal of the American College of Surgeons.

[32]  M. Lagios Heterogeneity of duct carcinoma in situ (DCIS): relationship of grade and subtype analysis to local recurrence and risk of invasive transformation. , 1995, Cancer letters.

[33]  L. Liotta,et al.  Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer. , 1995, Cancer research.

[34]  D Rutovitz,et al.  Computer image analysis of comparative genomic hybridization. , 1995, Cytometry.

[35]  F. Vicini,et al.  Outcome and prognostic factors for local recurrence in mammographically detected ductal carcinoma in situ of the breast treated with conservative surgery and radiation therapy. , 1995, International journal of radiation oncology, biology, physics.

[36]  N. Dracopoli,et al.  Current protocols in human genetics , 1994 .

[37]  W. Dupont,et al.  p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[38]  H. Oberman,et al.  Tumors of the Mammary Gland , 1994 .

[39]  B Fisher,et al.  Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. , 1993, The New England journal of medicine.

[40]  D. Pinkel,et al.  Comparative Genomic Hybridization for Molecular Cytogenetic Analysis of Solid Tumors , 2022 .